HORA RPE65
Alternative Names: HORA-RPE65Latest Information Update: 23 Jul 2021
At a glance
- Originator French Muscular Dystrophy Association; INSERM; Nantes University Hospital; University Hospital of Montpellier
- Developer Coave Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Leber congenital amaurosis